@article{edd827a5e2504d60829fc786d9bbe03f,
title = "Limitations of the PRODIGE 7 trial",
keywords = "Colorectal Neoplasms/drug therapy, Cytoreduction Surgical Procedures, Humans, Hyperthermic Intraperitoneal Chemotherapy, Leucovorin/therapeutic use, Peritoneal Neoplasms",
author = "Rovers, \{Koen P.\} and Kok, \{Niels F. M.\} and Punt, \{Cornelis J. A.\} and Tanis, \{Pieter J.\} and \{de Hingh\}, \{Ignace H. J. T.\}",
note = "Funding Information: CJAP reports serving as an advisor for Servier and Nordic Pharma. PJT reports receiving an unrestricted research grant from Allergan (LifeCell) unrelated to the present correspondence. IHJTdH reports receiving grants (paid to institute) from F Hoffmann-La Roche and QP\&S/RanD Biotech unrelated to the present correspondence. KPR and NFMK declare no competing interests.",
year = "2021",
month = may,
doi = "10.1016/S1470-2045(21)00063-2",
language = "English",
volume = "22",
pages = "E174--E174",
journal = "Lancet oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd",
number = "5",
}